PSA After TURP and Eligard Treatment
PSA should decrease substantially after both TURP and Eligard (leuprolide acetate) treatment, typically reaching very low levels (often <2 ng/mL after TURP alone, and near-undetectable with androgen deprivation therapy), and any persistent elevation warrants investigation for residual or recurrent prostate cancer.
Expected PSA Dynamics
After TURP Alone
PSA levels drop dramatically following TURP for benign prostatic tissue:
- Magnitude of decrease: PSA typically falls by 60-71% within 60 days post-TURP 1, 2
- Expected nadir: 90% of patients achieve PSA <4 ng/mL and 98% achieve <10 ng/mL after complete TURP with benign histology 1
- Timeline: The reduction peaks at 60 days and stabilizes thereafter 2
- Long-term levels: PSA continues to decline steadily, reaching median values of 0.6 ng/mL by 48 months 3
Each gram of resected tissue decreases PSA by approximately 0.15 ng/mL, and each 1% of prostate volume removed reduces PSA by 2.4% 2.
After Eligard (Leuprolide Acetate) Treatment
The FDA label for Eligard explicitly states that response should be monitored by periodic measurement of both testosterone and PSA 4. With effective androgen deprivation:
- Castrate testosterone levels are generally reached within 2-4 weeks
- PSA nadir should be achieved and monitored as a marker of treatment response
- In patients with metastatic disease, **failure to achieve PSA nadir <4.0 ng/mL at 7 months** is associated with poor survival (median ~1 year), while PSA nadir of 0.2 ng/mL correlates with median survival >6 years 5
- For non-metastatic disease after surgery/radiation, PSA nadir >0.2 ng/mL within 8 months of androgen suppression is associated with 20-fold greater risk of prostate cancer-specific mortality 5
Combined Effect (TURP + Eligard)
When both interventions are used together:
- Expect additive PSA suppression: TURP removes benign prostatic tissue (reducing baseline PSA production), while Eligard suppresses remaining prostatic tissue function
- Target PSA: Should approach near-undetectable levels if no cancer is present
- Monitoring is critical: The FDA label emphasizes that testosterone and PSA should be measured periodically to assess treatment response 4
Clinical Interpretation and Red Flags
When PSA Remains Elevated
Persistent elevation suggests:
- Residual or recurrent prostate cancer - most concerning possibility
- Inadequate androgen suppression - verify castrate testosterone levels achieved
- Incomplete TURP - significant benign tissue remaining
- Castration-resistant disease - if testosterone is suppressed but PSA rising
Critical Thresholds
- After TURP with benign pathology: PSA should be <4 ng/mL, ideally <2 ng/mL 3, 1
- On androgen deprivation: PSA nadir <0.2 ng/mL within 8 months is optimal 5
- Rising PSA on treatment indicates treatment failure and requires investigation with advanced imaging (PSMA PET/CT preferred) 6
Monitoring Algorithm
- Baseline: Measure PSA and testosterone before starting Eligard
- Early phase (weeks 1-2): PSA may transiently increase due to testosterone flare from GnRH agonist 4
- 2-4 weeks: Verify castrate testosterone achieved (<50 ng/dL)
- 60 days post-TURP: Expect peak PSA reduction from surgery 2
- 3-6 months: Establish new PSA nadir - should be very low
- Ongoing: Monitor PSA every 3-6 months; any confirmed rise indicates progression
Common Pitfalls
- Ignoring the testosterone flare: Initial PSA rise in first 1-2 weeks on Eligard is expected and not concerning 4
- Not verifying castrate levels: PSA suppression requires adequate testosterone suppression - always confirm
- Accepting elevated PSA as "normal": After both TURP (benign) and effective ADT, PSA should be very low; persistent elevation demands investigation
- Delayed investigation: Rising PSA on treatment represents disease progression requiring prompt imaging and management adjustment 6
Bottom line: In the context of TURP for benign disease followed by Eligard treatment, PSA should reach very low levels. Persistent elevation or rising PSA indicates either inadequate treatment response or underlying malignancy requiring further evaluation.